DELRAY BEACH, Fla. , Oct. 3, 2024 /PRNewswire/ -- The global clinical trial imaging market is on track to grow from USD 1.
42 billion in 2024 to USD 2.07 billion by 2029, with a compound annual growth rate (CAGR) of 7.8%.
This growth is driven by increased research and development funding in pharmaceuticals and biotechnology, coupled with a rise in Contract Research Organizations (CROs). However, high costs associated with imaging equipment and services may hinder expansion. The services segment currently dominates the market, reflecting a demand for comprehensive clinical study support, while computed tomography holds the largest share among imaging modalities.
North America leads in market share due to its advanced R&D and aging population. Emerging economies like India and China also present significant growth opportunities, especially as they attract investment in clinical trials. Key players in the market include ICON plc, Clario, and IXICO, which are innovating to enhance clinical trial efficiencies.
Overall, the clinical trial imaging market is poised for substantial growth driven by rising drug development demands and advancements in imaging technologies..